DOCSLIB.ORG

Infergen II-15

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Infergen II-15 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT INFERGEN 9 micrograms solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION OF ACTIVE SUBSTANCE INFERGEN contains as active substance interferon alfacon-1 (previously referred to as consensus interferon (CIFN)). It is provided as a solution containing 9 micrograms in 0.3 ml (30 micrograms/ml). Interferon alfacon-1 is a protein of 166 amino acids. The amino acid sequence represents a consensus sequence (the most commonly appearing amino acids at each locus) of 14 naturally occurring human type-1 interferons. The DNA coding sequence was synthesised based on the derived consensus sequence and the molecule was cloned into an Escherichia coli expression system by means of recombinant DNA techniques. 3. PHARMACEUTICAL FORM Solution for injection. Infergen is a clear and colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of patients of 18 years and older with histologically proven chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease. Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C. 4.2 Posology and method of administration The treatment with INFERGEN should be initiated under the supervision of a physician experienced in the treatment of the disease. Posology Adults: 9 micrograms three times a week, administered subcutaneously as a single injection. The total weekly dosage of interferon alfacon-1 should be equally divided over the week, preferably at least 48 hours should elapse between consecutive doses. The optimal duration of therapy with interferons is not yet fully established but a therapy of at least 12 months is currently advised. In patients showing no improvement after 3-4 months treatment with 9 micrograms, discontinuation of therapy should be considered. During the course of treatment with INFERGEN if adverse reactions develop, the dosage should be reduced or the therapy should be discontinued until the adverse reactions abate. Therapy should be resumed as soon as the adverse events become tolerable. INFERGEN dose reduction below 7.5 micrograms is not recommended. If persistent or recurrent intolerance develops following adequate dosage adjustment, or disease progresses, treatment should be discontinued. Children: The safety and efficacy of INFERGEN in children and adolescents of less than 18 years with chronic hepatitis C virus infection have not been studied. 4.3 Contra-indications - patients with known hypersensitivity to the active substance or to any of the excipients; - patients with epilepsy or a history of severe psychiatric disorders such as severe depression, suicidal ideation or other severely compromised patients with central nervous system disorders (see also section 4.4); - severe pre-existing cardiac disease; - severe renal or hepatic dysfunction; - patients with decompensated liver disease; - chronic hepatitis in patients who are or have been treated recently with immunosuppressive therapy excluding short term corticosteroid withdrawal; - autoimmune hepatitis; or history of autoimmune disease; immunosuppressed transplant recipients - pre-existing thyroid disease unless adequately controlled with conventional treatment. 4.4 Special warnings and special precautions for use - Interferon alfacon-1 should be used cautiously in patients with severe leukopenia or thrombocytopenia or who are receiving agents that are known to cause myelosuppression. Leukopenia, particularly granulocytopenia, may be severe in patients treated with alpha interferons, including interferon alfacon-1, and may necessitate dose reduction or temporary dose cessation. Thrombocytopenia is a common, but less severe, event often associated with alpha interferon therapy. Therapy should be withheld if the absolute neutrophil count (ANC) is < 500X106/L or if the platelet count is < 50X109/L. - Patients to be treated with interferon alfacon-1 should be informed that depressive disorders and suicidal ideation and other alterations of mental status, may be undesirable effects of interferon treatment and should report these symptoms to the prescribing physician immediately. Discontinuation of therapy should be considered. - Patients with a history of congestive heart failure, myocardial infarction and/or previous or current arrhythmic disorders who require interferon alfacon-1 therapy should be closely monitored. - Treatment with interferon alfacon-1 should be discontinued in patients with hepatitis who develop signs of liver decompensation. - Clinical manifestation of autoimmune disease during interferon therapy may occur frequently in patients predisposed to the development of autoimmune disease. - Serious acute hypersensitivity reactions have been reported in rare instances following treatment with alpha interferons. If hypersensitivity reactions occur (e.g., anaphylaxis, bronchoconstriction, pharyngeal edema, angioedema, urticaria), the drug should be discontinued immediately and appropriate medical treatment instituted. - Because of a risk of exacerbation of pre-existing psoriasis during interferon treatment, interferon alfacon-1 should be used in such patients only if the potential benefit outweighs the potential risk. - Ophthalmologic disorders have been reported in patients being treated with interferon alfacon-1. Any patient complaining of changes in visual acuity or visual fields or reporting other ophthalmologic symptoms during treatment should have an eye examination. A baseline ocular examination is recommended prior to treatment with interferon in patients with diabetes mellitus or hypertension. - Hypotension may occur during interferon therapy and may require supportive treatment. - Hypotension due to fluid depletion can occur and may require fluid replacement. - While fever may be associated with the flu-like syndrome, which occurs during therapy, other causes of fever should be ruled out. Flu-like symptoms can be controlled by bedtime administration of interferon alfacon-1 or symptomatically treated with analgesics like paracetamol. - Interferon alfacon-1 should be used cautiously in patients with coagulation disorders or debilitating medical conditions e.g. history of pulmonary disease such as chronic obstructive bronchitis, and diabetes mellitus prone to ketoacidosis. - Diabetes mellitus may be aggravated or may develop in patients with chronic hepatitis C infection treated with alpha interferons. Interferon alfacon-1 should be used with caution in patients with diabetes mellitus or a history of diabetes. - Pulmonary infiltrates, pneumonitis interstitial pneumonia and pneumonia have been observed rarely during interferon therapy in patients with chronic hepatitis C. Patients developing fever, cough, dyspnea, or other respiratory symptoms should have a chest X-ray taken. If necessary interferon therapy should be discontinued and corticosteroids may be indicated. - If patients treated for chronic hepatitis C with interferon alfacon-1 develop thyroid abnormalities, either hypothyroid or hyperthyroid, the abnormalities should be controlled by conventional therapy for thyroid dysfunction. Pre-existing abnormalities should also be controlled before initiation of interferon therapy. - If alanine aminotransferase flares during therapy, treatment may be continued unless signs and symptoms of liver failure are observed. - There are significant differences in specific activities among interferons. It should be realised that switching from one interferon to another may require adjustments of dosage and/or route of administration. 4.5 Interaction with other medicinal products and other forms of interaction Interferon alfacon-1 may depress the level and activity of cytochrome P450 enzymes (based on animal data). Plasma levels of active substances, known to be metabolised by these enzymes, may increase when these are given together with INFERGEN. INFERGEN should be used cautiously in patients who are receiving agents known to be metabolized by this pathway. Patients taking drugs that are metabolized by this pathway should be monitored closely for changes in the therapeutic and/or toxic levels of concomitant drugs. Currently there are no data available from formal interaction studies with INFERGEN and other medicinal products. 4.6 Use during pregnancy and lactation Use during pregnancy No studies have been conducted in pregnant women. Although in animal tests interferon alfacon-1, when administered during pregnancy, did not reveal teratogenic effects, - foetal harm such as growth retardation, cannot be excluded. In reproduction toxicity tests in animals, doses greatly in excess of the recommended clinical dose showed an abortifacient effect. In pregnancy, interferon alfacon-1 should be administered only if the benefit to the woman outweighs the potential risk to the foetus. Adequate contraceptive precautions should be advised if either partner is receiving interferon alfacon-1. Use during lactation It is not known whether interferon alfacon-1 is excreted in human milk. A decision must be taken whether to suspend breast feeding or to discontinue administration, taking into account the importance of the medicinal product to the mother. 4.7 Effects on ability to drive and use machines Patients who develop flu-like symptoms, dizziness, depressive symptoms, confusion, somnolence and fatigue should be cautioned
Load more

Recommended publications
  • R&D Briefing 76
    The Impact of Recent Regulatory Developments on the Mexican Therapeutic Landscape Access to innovative medicines is key to El acceso a medicamentos innovadores es clave para improving overall population health, reducing mejorar la salud de toda la población, para reducir los hospitalisation time and decreasing morbidity and tiempos de hospitalización, la morbilidad y la mortalidad mortality. An efficient regulatory process can be de un país. Un proceso regulatorio eficiente tiene un reflected in measurable positive health impacts; impacto positivo medible en la salud, y por el contrario, conversely, activities that slow or impede acciones que retrasan o impiden la eficiencia regulatoria y regulatory efficiency and predictability can be su predictibilidad pueden ser perjudiciales. La parálisis detrimental. Recent developments in the Mexican reciente del Sistema regulatorio mexicano respecto a la regulatory system for the assessments of evaluación de nuevos medicamentos innovadores innovative new products have had a negative conlleva un impacto negativo en la salud de la población impact on Mexican public health. mexicana. This Briefing addresses the impact of suspending Este informe analiza el impacto de la suspensión de las the activities of the New Molecules Committee actividades del Comité de Moléculas Nuevas (NMC, por (NMC) on the Mexican therapeutic landscape. sus siglas en inglés) sobre el horizonte terapéutico de First, we compared the way that “new medicines” México. En primer lugar, comparamos la definición de are defined within the context of the Mexican nuevos medicamentos según el contexto regulatorio regulatory system, with definitions used by mexicano con las definiciones adoptadas por otras comparable regulators and health organisations. agencias reguladoras u organizaciones de salud del We have also investigated the extent to which mundo.
    [Show full text]
  • Renal Clinical Pharmacy Services“
    DISSERTATION „Renal clinical pharmacy services“ Mag.pharm. Gunar Stemer angestrebter akademischer Grad Doktor der Naturwissenschaften (Dr.rer.nat.) Wien, 2011 Studienkennzahl lt. Studienblatt: A 091 449 Dissertationsgebiet lt. Studien- Pharmazie blatt: Betreuerin / Betreuer: Ao. Univ. Prof. Mag. Dr. Rosa Lemmens 2 e pensando di lei mi sopragiunse uno soave sonno ego dominus tuus vide cor tuum e d’esto core ardendo cor tuum lei paventosa umilmente pascea appreso gir io ne vedea piangendo la letizia si convertia in amarissimo pianto io sono in pace cor meum io sono in pace vide cor meum Dante Alighieri La Vita Nuova ~1293 Gewidmet meinen Eltern Annelies und Franz, in aufrichtiger Dankbarkeit und Liebe Dedicated to my parents Annelies and Franz, in sincere gratitude and love 3 4 ACKNOWLEDGEMENTS This thesis would not have been possible without the continuous support, help, and contributions of so many colleagues, companions, friends, and beloved family members. First, I want to express my deepest gratitude to my doctoral advisor, Mrs. Prof. Rosa Lemmens, for her commitment in supervising my thesis work, her support during the writing of this thesis, several constructive discussions with her, and her critical comments. My sincerest thanks are extended to the head of the pharmacy department of the Vienna General Hospital, Mrs. SR Mag. Elfriede Dolinar, for providing me with this unique opportunity to work on the topic of clinical pharmacy and, thus, contribute to the evolution of the complete hospital pharmacy and clinical pharmacy discipline in Austria. I would like to thank her for her trust in my capabilities to succeed in this demanding project over the last three years by implementing new services, her vision regarding the discipline of hospital pharmacy, her overall contribution to the development of the profession of hospital pharmacy, and her continuous belief in the value of clinical pharmacy services.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Etoposide ”Ebewe ” 20 mg/ml – Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate for solution for infusion contains 20 mg of etoposide. 1, 5, or 10 vials of 2.5 ml concentrate for solution for infusion contains 50 mg etoposide. 1, 5, or 10 vials of 5 ml concentrate for solution for infusion contains 100 mg etoposide. 1, 5, or 10 vials of 10 ml concentrate for solution for infusion contains 200 mg etoposide. 1, 5, or 10 vials of 20 ml concentrate for solution for infusion contains 400 mg etoposide. 1, 5, or 10 vials of 50 ml concentrate for solution for infusion contains 1000 mg etoposide. Excipients: Benzyl alcohol, ethanol. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, light yellow solution. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Etoposide is a antineoplastic agent for intravenous use. It can be used alone or in combination with other oncolytic agents. Available data show that etoposide may be used in treatment of small -celled lung cancer, resistant non -seminomatous testicular carcinoma, acute myelomonocytic and myelocytic leukaemia (AML, FAB subtype M4 or M5) as part of combination therapy after failure of induction chemotherapy. 4.2 Posology and method of administration Etoposide should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents. Pregnant personnel should not handle chemotherapeutic agents.
    [Show full text]
  • ORG Medicamentos Alto Impacto Econo Mico Maquetaciûn 1
    Rev. OFIL·ILAPHAR 2020 [first on line] / ORIGINAL / 1 Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalaria FORTES-GONZÁLEZ MS, VAZQUEZ-BLANCO S, HERRERO-POCH L, DE MIGUEL-BOUZAS JC, CASTRO-DOMÍNGUEZ JM, VILLAMAYOR-BLANCO L Servicio de Farmacia Hospitalaria. Hospital Povisa. Vigo (España) Fecha de recepción: 19/10/2020 - Fecha de aceptación: 24/11/2020 RESUMEN los MAC fueron innovadores, 26,5% huérfanos y 34,0% Objetivos: Los medicamentos de alto impacto económico biológicos. Dieciséis medicamentos tuvieron un coste (MAIE) constituyen un reto para los servicios de salud pú- >10.000 €/envase. Los MEC pertenecieron principalmente blicos de los países europeos. Sin embargo, no existe con- al grupo L (45,0%) y J (35,0%). El PVL medio diario de los senso sobre qué constituye un MAIE. El objetivo del estudio MEC fue 154,4 € (1,1-1.629,3). El 35,5% fueron innova- fue configurar una lista de MAIE dispensados por los servi- dores, 5,0% huérfanos y 60,0% biológicos. cios de farmacia hospitalarios y analizar la situación respecto Conclusiones: Un elevado número de MAIE son dispensados a estos fármacos en España. por los servicios de farmacia hospitalarios, principalmente Métodos: Se consideraron MAIE aquellos fármacos con un antineoplásicos y antiinfecciosos. Aunque el PVL mínimo coste >10.000 €/año (MAC) o con un elevado volumen de diario para considerar un medicamento de alto impacto es consumo (MEC). Se estimaron los precios (PVL) por dosis 27,4 €, el PVL medio diario de los MAC fue >200 €. Sin diaria definida o dosis diaria prescrita. embargo, el elevado consumo de algunos fármacos, hace Resultados: Un total de 147 principios activos fueron consi- que medicamentos con un coste tan bajo como 1,1 € pue- derados MAC, correspondiendo mayoritariamente con los dan ser considerados MAIE.
    [Show full text]
  • ORG Medicamentos Alto Impacto Econo Mico Maquetaciûn 1
    Rev. OFIL·ILAPHAR 2020 [first on line] / ORIGINAL / 1 Medicamentos de alto impacto económico y sanitario en la prestación farmacéutica hospitalaria FORTES-GONZÁLEZ MS, VAZQUEZ-BLANCO S, HERRERO-POCH L, DE MIGUEL-BOUZAS JC, CASTRO-DOMÍNGUEZ JM, VILLAMAYOR-BLANCO L Servicio de Farmacia Hospitalaria. Hospital Povisa. Vigo (España) Fecha de recepción: 19/10/2020 - Fecha de aceptación: 24/11/2020 RESUMEN los MAC fueron innovadores, 26,5% huérfanos y 34,0% Objetivos: Los medicamentos de alto impacto económico biológicos. Dieciséis medicamentos tuvieron un coste (MAIE) constituyen un reto para los servicios de salud pú- >10.000 €/envase. Los MEC pertenecieron principalmente blicos de los países europeos. Sin embargo, no existe con- al grupo L (45,0%) y J (35,0%). El PVL medio diario de los senso sobre qué constituye un MAIE. El objetivo del estudio MEC fue 154,4 € (1,1-1.629,3). El 35,5% fueron innova- fue configurar una lista de MAIE dispensados por los servi- dores, 5,0% huérfanos y 60,0% biológicos. cios de farmacia hospitalarios y analizar la situación respecto Conclusiones: Un elevado número de MAIE son dispensados a estos fármacos en España. por los servicios de farmacia hospitalarios, principalmente Métodos: Se consideraron MAIE aquellos fármacos con un antineoplásicos y antiinfecciosos. Aunque el PVL mínimo coste >10.000 €/año (MAC) o con un elevado volumen de diario para considerar un medicamento de alto impacto es consumo (MEC). Se estimaron los precios (PVL) por dosis 27,4 €, el PVL medio diario de los MAC fue >200 €. Sin diaria definida o dosis diaria prescrita. embargo, el elevado consumo de algunos fármacos, hace Resultados: Un total de 147 principios activos fueron consi- que medicamentos con un coste tan bajo como 1,1 € pue- derados MAC, correspondiendo mayoritariamente con los dan ser considerados MAIE.
    [Show full text]
  • International Price Comparison of Pharmaceuticals 2017
    International price comparison of pharmaceuticals 2017 – a volume based analysis of Swedish pharmaceutical prices and volumes relative to 19 other European coun- tries. 2 (101) You are welcome to quote Dental and Pharmaceutical Benefits Agency reports, but please remember to cite the source: the report’s name, year and Dental and Phar- maceutical Benefits Agency. Dental and Pharmaceutical Benefits Agency, February 2018 Authors: Emil Aho, Pontus Johansson and Gunilla Rönnholm. Reference number: 3611/2017 Postal address: Box 22520, 104 22 Stockholm Visiting address: Fleminggatan 18, Stockholm Telephone: +46 8 568 420 50 www.tlv.se 3 (101) Preface The Dental and Pharmaceutical Benefits Agency’s (TLV’s) mandate includes moni- toring and analysing the price development of pharmaceuticals from an interna- tional perspective. In this report, TLV presents the results of the analysis of price and volume data for the first quarter of 2014, 2015, 2016 and 2017 in Sweden in comparison with 19 other European countries. The segments analysed are pharmaceuticals not exposed to competition and pharmaceuticals exposed to competition, with the latter includ- ing all pharmaceuticals available as substitutable medicines in the product-of-the- month system as per March 2017. The report should be viewed as a basis for further analysis of the dynamics of Swe- dish prices and price changes compared to that seen internationally. Sofia Wallström Director-General 4 (101) 5 (101) Table of contents Preface ..................................................................................................................
    [Show full text]
  • A Plea to Systematically Assess the Real-World Cost-Effectiveness Of
    Erasmus Universiteit Rotterdam Handling uncertainty: a plea to systematically assess the real-world cost-effectiveness of expensive outpatient medicines Cost-effectiveness review and critical evidence appraisal for pharmaceutical products potentially benefitting most from unrevised reimbursement in the Netherlands Frank G. Sandmann [Rotterdam, November 2011] - i - A thesis submitted to the Institute of Health Policy and Management at the Erasmus University Rotterdam, the Netherlands, in partial fulfilment of the requirements for the degree of Master of Science in Health Economics, Policy and Law with a specialisation in ‘ Health Economics ’. Rotterdam, 30 November 2011 Thesis Supervisor Dr. Marc Koopmanschap – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Co-Readers Prof. dr. Adri Steenhoek – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Dr. Ken Redekop – institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam Frank Gerd Sandmann Student of Health Economics (349997) Institute of Health Policy and Management (iBMG) & Erasmus School of Economics (ESE) Erasmus University Rotterdam, Rotterdam, The Netherlands - ii - Dedication Gewidmet meinen Großeltern Margret und Josef Feilen. - iii - Acknowledgements I would like to thank my daily supervisor Marc Koopmanschap for his comments, expertise, and kind supportive attitude. You truly mastered the ‘open-door’ policy and I always felt good taken care of. A positive outlook on life can make a lot look so much easier than expected. I also highly value the effort from Wil Toenders for his comments on a preliminary concept version of the text parts for the two medications imatinib and pegfilgrastim. I would like to thank Adri Steenhoek and Margreet Franken. Our work was inspiration for me and this thesis! My great sense of appreciation goes to my friends Clare Ninsiima, René Miller, and Ilja Löwen.
    [Show full text]
  • Utilization and Expenditure of Anti-Cancer Medicines in Kosovo: Findings and Implications
    PharmacoEconomics Open (2018) 2:423–432 https://doi.org/10.1007/s41669-017-0066-8 ORIGINAL RESEARCH ARTICLE Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications 1,2 3,4,5 5 5 Arianit Jakupi • Brian Godman • Antony Martin • Alan Haycox • Indrit Baholli6 Published online: 2 February 2018 Ó The Author(s) 2018. This article is an open access publication Abstract Method National drug utilization data is available in Background and Objective The Ministry of Health (MoH) Kosovo. Utilization and expenditure on anti-cancer leads and organizes health policy in Kosovo, which medicines [Anatomical Therapeutic Chemical (ATC) code includes procurement and provision of medicines, includ- L], initially from 2011 to 2013, especially for anti-cancer ing anti-cancer medicines, which compose a special group medicines on the essential medicines list was analysed of medicines. However, there has been limited analysis of from national data. In addition, current systems for the utilization and expenditure on anti-cancer medicines in procuring and managing anti-cancer medicines in Kosovo Kosovo; consequently, the objective of this study is to was documented. undertake research to provide future guidance on the use of Results There was appreciable variability in the utilization anti-cancer medicines. of anti-cancer medicines over the years, with low or limited use of some anti-cancer medicines on the Essential Medi- cine List. This is a concern in view of their essential & Brian Godman medicine status. From 2011 to 2013, €16.49 million was [email protected]; [email protected]; spent on anti-cancer medicines (ATC L).
    [Show full text]
  • Jatros-2018-02
    EUR 9,– Jahrgang 23/2018 Österreichische Post AG, MZ 09Z038204M, Retouren an PF555, 1008 Wien ISSN 1997-8308, Universimed CMC GmbH, Markgraf-Rüdiger-Straße 6–8, 1150 Wien Offizielles Medium der ÖGO, ÖGU und ÖGOuT 2 / 2018 Orthopädie & Traumatologie www.universimed.com Rheumatologie © iStockphoto.com/video-doctor © iStockphoto.com/video-doctor Knochengesundheit | Seite 9 Osteoporose in der orthopädischen Praxis Wirbelsäulenchirurgie | Seite 26 Der zervikothorakale Übergang – eine besondere Herausforderung ACR/ARHP | Seite 57 Good News from San Diego Inserat_A4 19.12.17 13:08 Seite 1 26. OSTEOPOROSE FORUM 3. - 5. Mai 2018 St. Wolfgang Eventresort Hotel scalaria Gynäkologie, Orthopädie und Knochen Tagungspräsidentin: Neue Leitlinien: Univ.-Doz. Dr. Astrid Fahrleitner-Pammer DVO Arznei und Vernunft Tagungssekretär: Prim. Dr. Peter Bernecker Knochen, Niere, Gefäße Ernährung und Knochen Neues und „Hands on“ in der Osteologie Kongress-Büro: Aus der Praxis Wiener Medizinische Akademie, Alser Straße 4, 1090 Wien für die Praxis T: +43 1 405 1383-17 F: +43 1 4078274 E: [email protected] Fachausstellung: Hotelreservierung: „Rare bone MAW - Medizinische Ausstellungs- Reisebüro PRO TRAVEL diseases” und Werbegesellschaft Pilgerstraße 152 Freyung 6, 1010 Wien 5360 St.Wolfgang Sekundäre T: +43 1 53663-48 F: +43 1 5356016 T: +43 6138 25250 Osteoporose E: [email protected], [email protected] F: +43 6138 3054 www.medacad.org/osteoporose2018 Editorial G. Holzer, Wien ORTHOPÄDIE & TRAUMATOLOGIE RHEUMATOLOGIE Osteoporose und ihre sekundäre Prophylaxe Die Osteoporose wird auch als „silent disease“ – als stille nur mehr etwa die Hälfte nach wie vor unter einer Therapie Erkrankung – bezeichnet. Das ist ein Grund dafür, dass sie befindet. Das ist dramatisch.
    [Show full text]
  • Download Jahresbericht Kantonsapotheke 2014
    Kanton Zürich Gesundheitsdirektion Kantonsapotheke 205. Jahresbericht Kantonsapotheke Zürich 2014 205. Jahresbericht Kantonsapotheke Zürich 2014 Während 24 Stunden an 365 Tagen im Jahr – die Kantonsapotheke ist ein verlässlicher Partner im Gesundheitswesen für • Patienten • Spitäler • Heime • Rettungsorganisationen • Ärzte • Pflegepersonal • Bevölkerung • Industrie Allgemeines Die Kantonsapotheke Zürich (KAZ) ist als Dienst- Die Kantonsapotheke Zürich arbeitet eng mit ihren leistungsbetrieb der Gesundheitsdirektion des Kantons Partnern zusammen, sie ist vor Ort und in die Prozesse Zürich Partnerin des Universitätsspitals Zürich (USZ), integriert. Wir kennen und erfüllen den Bedarf unserer des Kantonsspitals Winterthur (KSW), der Psychiat- Partner. Da wir über das aktuellste pharmazeutische rischen Universitätsklinik (PUK) und verschiedener Wissen verfügen, können wir stets objektive fachliche kantonaler Krankenhäuser und Institute. Als eines der Beratung für alle Anspruchsgruppen gewährleisten. führenden spitalpharmazeutischen Kompetenzzentren der Schweiz verfügt sie über einen gesetzlichen Der Jahresbericht gibt einen Einblick in die im Jahr Versorgungsauftrag. Die Kantonsapotheke erbringt 2014 erbrachten Leistungen im Rahmen unserer ein breites Spektrum von Leistungen rund um das Kernkompetenzen Heilmittel auf dem höchstmöglichen Niveau bezüglich Qualität und Wirtschaftlichkeit. Dabei orientieren • Fachberatung und Wissensvermittlung wir uns an den neusten Technologien und setzen • Versorgungskette aktuellstes pharmazeutisches Know-how
    [Show full text]
  • Original Adverse Drug Reactions of Antineoplastic And
    Adverse drug reactions of antineoplastic and immunomodulating agents reported to the Egyptian Pharmaceutical Vigilance Center Original Samar O. Gouda1, Amr A. Saad2, Maggie M. Abbassi1, and Samar F. Farid1 Article 1Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University 2Egyptian Pharmaceutical Vigilance Center ABSTRACT The aim of this study was to evaluate the pattern of Adverse Drug Reactions (ADRs) related to antineoplastic and immunomodulating agents in Egypt. We extracted all ADR reports of antineoplastic and immunomodulating agents (Anatomical Therapeutic Chemical (ATC) code L) that were reported to Egyptian Pharmaceutical Vigilance Center (EPVC) from January 2011 to December 2015 using VigiLyze TM. Afterwards, these reports were analyzed and categorized by age, sex, reporter qualification, seriousness, type of ADRs, medications, indications of use and causality. During the study period, 1905 reports related to antineoplastic and immunomodulating agents were received; 44.6% of which were reported by consumers and 56.8% by health care professionals. ADRs were serious in 13.3% and 65.1% of the cases reported by consumers and healthcare professionals, respectively. Approximately half (52.5%) of the reported ADRs occurred in females and only 8.4% occurred in children. Half of the reported ADRs ( 51.5%) occurred in middle aged group (45- 64 years). The most reported classes at the therapeutic level were immunostimulants (ATC code L03) and antineoplastic agents (ATC code L01). The most frequently reported medication was peg-interferon alfa-2a. The majority of ADRs were of the type "general disorders and administration site conditions" and "gastrointestinal disorders". In conclusion, ADRs caused by immunostimulants especially interferons have higher tendency to be reported in Egypt especially in the middle-aged group.
    [Show full text]
  • Orphan Drugs Regulatory Framework, Market Positioning and Major Development Challenges and Strategies
    Inês Patrícia Ferreira Amaral ORPHAN DRUGS REGULATORY FRAMEWORK, MARKET POSITIONING AND MAJOR DEVELOPMENT CHALLENGES AND STRATEGIES Dissertação de Mestrado em Biotecnologia Farmacêutica, orientada pela Professora Doutora Maria Dulce Cotrim e pela Doutora Ana Catarina Pinto (Bluepharma, Indústria Farmacêutica SA) e apresentada à Faculdade de Farmácia da Universidade de Coimbra Julho 2016 Inês Patrícia Ferreira Amaral ORPHAN DRUGS REGULATORY FRAMEWORK, MARKET POSITIONING AND MAJOR DEVELOPMENT CHALLENGES AND STRATEGIES Dissertação de Mestrado em Biotecnologia Farmacêutica, orientada pela Professora Doutora Maria Dulce Cotrim e pela Doutora Ana Catarina Pinto (Bluepharma, Indústria Farmacêutica SA) e apresentada à Faculdade de Farmácia da Universidade de Coimbra Julho 2016 Agradecimentos Nesta fase várias foram as pessoas que passaram na minha vida e por uma ou por outra razão deixaram um pequeno pedaço de si. No entanto quero agradecer, em particular: À Professora Doutora Maria Dulce Cotrim, Professora da Faculdade de Farmácia da Universidade de Coimbra, por se ter disponibilizado para orientar esta dissertação. Ao Professor Doutor Sérgio Simões, Professor da Faculdade de Farmácia da Universidade de Coimbra e Chairman da Luzitin S.A, por me ter dado o prazer de concretizar este trabalho em parceria com a Luzitin. À Doutora Ana Catarina Pinto, orientadora desta dissertação na Luzitin, por toda a disponibilidade, dedicação, apoio incondicional, compreensão ao longo do trabalho e principalmente por estar sempre presente na orientação desta minha dissertação. Aos meus pais, que vivem comigo desde sempre as alegrias e tristezas desta caminhada, sem vocês isto não tinha sentido. Agradeço todo o esforço que fazem para tornarem possível a realização dos meus desejos, por todos os valores que me transmitem e toda a preocupação que têm comigo.
    [Show full text]